PDLIM2 and lung carcinoma: Although reversal of PDLIM2 epigenetic repression by epigenetic drugs to restore PDLIM2 expression in cancer cells may be used to treat lung cancer (Sun et al., 2019), it is logical that this approach cannot be applied to lung tumors involving PDLIM2 LOH, which accounts for about 58% of all lung cancer cases.